ARCHIVES

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

This article is from The Cancer Letter archive.

Vol. 38 No. 07 | February 17, 2012

Download PDF Visit The Full Archive

Related Articles

CIS Recompetition Approved, But BSC Delays Decision On Matching Requirement

May 15, 1987

FASEB Seeks $27.3B For NIH, Increases For Research, Training, And Infrastructure.

February 1, 2002

An old drug’s 21st century makeover begins with 84-fold price increase. Price hike of procarbazine astonishes brain tumor specialists.

May 13, 2005

Research Dollars Save Money, Lives, Scientists Tell Senate

May 3, 1991

House Appropriations Adds $20 Mil. To Bush Request For NCI, Emphasizes Three Cancers

June 28, 1991

FDA Encourages Randomized Trials For Medical Devices.

May 26, 2006